Peptide-based PET quantifies target engagement of PD-L1 therapeutics
Date
2019Journal
Journal of Clinical InvestigationPublisher
American Society for Clinical InvestigationType
Article
Metadata
Show full item recordAbstract
Immune checkpoint therapies have shown tremendous promise in cancer therapy. However, tools to assess their target engagement, and hence the ability to predict their efficacy, have been lacking. Here, we show that target engagement and tumor-residence kinetics of antibody therapeutics targeting programmed death ligand-1 (PD-L1) can be quantified noninvasively. In computational docking studies, we observed that PD-L1-targeted monoclonal antibodies (atezolizumab, avelumab, and durvalumab) and a high-affinity PD-L1-binding peptide, WL12, have common interaction sites on PD-L1. Using the peptide radiotracer [64Cu]WL12 in vivo, we employed positron emission tomography (PET) imaging and biodistribution studies in multiple xenograft models and demonstrated that variable PD-L1 expression and its saturation by atezolizumab, avelumab, and durvalumab can be quantified independently of biophysical properties and pharmacokinetics of antibodies. Next, we used [64Cu]WL12 to evaluate the impact of time and dose on the unoccupied fraction of tumor PD-L1 during treatment. These quantitative measures enabled, by mathematical modeling, prediction of antibody doses needed to achieve therapeutically effective occupancy (defined as >90%). Thus, we show that peptide-based PET is a promising tool for optimizing dose and therapeutic regimens employing PD-L1 checkpoint antibodies, and can be used for improving therapeutic efficacy. Copyright 2018 American Society for Clinical Investigation. All right reserved.Sponsors
We would like thank the University of Wisconsin and Washington University Cyclotron teams for 64CuCl2 production. Funding for this study was provided by Allegheny Health Network-Johns Hopkins Cancer Research Fund (to SN), NIH 1R01CA236616 (to SN), and NIH P41EB024495 (to MGP). Core resources (flow cytometry, histology, and imaging) were supported by NIH P30CA006973.Keyword
programmed death ligand-1peptide-based PET
drug-target engagement
immune checkpoint therapeutics
Cancer--Treatment
Positron-Emission Tomography
Identifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85060855025&doi=10.1172%2fJCI122216&partnerID=40&md5=0e01ca87ec600363f7e1e39386eb90d0; http://hdl.handle.net/10713/8708ae974a485f413a2113503eed53cd6c53
10.1172/JCI122216
Scopus Count
Collections
Related articles
- Rapid PD-L1 detection in tumors with PET using a highly specific peptide.
- Authors: Chatterjee S, Lesniak WG, Miller MS, Lisok A, Sikorska E, Wharram B, Kumar D, Gabrielson M, Pomper MG, Gabelli SB, Nimmagadda S
- Issue date: 2017 Jan 29
- Peptide-Based <sup>68</sup>Ga-PET Radiotracer for Imaging PD-L1 Expression in Cancer.
- Authors: De Silva RA, Kumar D, Lisok A, Chatterjee S, Wharram B, Venkateswara Rao K, Mease R, Dannals RF, Pomper MG, Nimmagadda S
- Issue date: 2018 Sep 4
- Development of [<sup>18</sup>F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide.
- Authors: Lesniak WG, Mease RC, Chatterjee S, Kumar D, Lisok A, Wharram B, Kalagadda VR, Emens LA, Pomper MG, Nimmagadda S
- Issue date: 2019 Jan-Dec
- PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.
- Authors: Lesniak WG, Chatterjee S, Gabrielson M, Lisok A, Wharram B, Pomper MG, Nimmagadda S
- Issue date: 2016 Sep 21
- In Vivo Imaging of the Programmed Death Ligand 1 by <sup>18</sup>F PET.
- Authors: González Trotter DE, Meng X, McQuade P, Rubins D, Klimas M, Zeng Z, Connolly BM, Miller PJ, O'Malley SS, Lin SA, Getty KL, Fayadat-Dilman L, Liang L, Wahlberg E, Widmark O, Ekblad C, Frejd FY, Hostetler ED, Evelhoch JL
- Issue date: 2017 Nov